drugset / Trial / NCT06080698
Gram-Negative Bloodstream Infection Oral Antibiotic Therapy Trial
Recruiting
1030 enrolled
Johns Hopkins University
Patient-Centered Outcomes Research Institute · collab
RandomizedParallel-groupOpen-labelTreatment
Summary
The Gram-negative bloodstream infection Oral Antibiotic Therapy trial (The GOAT Trial) is a multi-center, randomized clinical trial that hypothesizes that early transition to oral antibiotic therapy for the treatment of Gram-Negative BloodStream Infection (GN-BSI) is as effective but safer than remaining on intravenous (IV) antibiotic therapy for the duration of treatment.
Timeline
- Start
- 2024-02-22
- Primary completion
- 2027-05-31
- Completion
- 2027-06-30
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Comparator | Amoxicillin | Other / unclassified | — | Intravenous |
| Comparator | Amoxicillin | Other / unclassified | — | — |
| Comparator | CEPHALEXIN ANHYDROUS | Small molecule | — | — |
| Comparator | Cefepime | Small molecule | — | Intravenous |
| Comparator | Ceftriaxone | Other / unclassified | — | Intravenous |
| Comparator | Ciprofloxacin | Small molecule | — | — |
| Comparator | Meropenem | Small molecule | — | Intravenous |
| Comparator | trimethoprim-sulfamethoxazole | Unknown | — | — |